14:50-15:10 Case-based lecture: Evolving therapies for myelofibrosis; John Mascarenhas (New York)
non-JAK inhibitor approaches
15:10-15:20 Interactive case: When to switch from Ruxolitinib Haifa Kathrin Al-Ali (Halle)
15:20-15:25 Genomic analysis of primary and secondary Myelofibrosis Damien Luque Paz (Angers)
redefines the prognostic impact of ASXL1 mutations: a FIM study
15:25-15:55 Panel discussion
SESSION V – Management of advanced and unusual disease (MPN and CML)
Chair: Claire Harrison (London)
15:55-16:00 Introduction Claire Harrison (London)
16:00-16:20 Case-based lecture: Management of rare translocations Andreas Reiter (Mannheim)
MPN entities FGFR1 and JAK2 partner geners
16:20-16:40 Case-based lecture: Allogeneic haematopoietic stem cell Nicolaus Kröger (Hamburg)
transplantation for Myelofibrosis & CML in advanced phase
16:40-17:00 Case-based lecture: Treatment strategies for blast phase Vikas Gupta (Toronto)
of MPN
17:00-17:20 Case-based lecture: Blast crisis in CML Dragana Milojkovic (London)
17:20-17:30 Interactive case: CMML Donal McLornan (London)
17:30-17:40 Interactive case: Venetoclax data Srdan Verstovsek (Houston)
17:40-17:45 CPI-0610, a bromodomain and extraterminal domain Francesco Passamonti (Varese)
protein (BET) inhibitor, in combination with ruxolitinib,
in JAK-Inhibitor-Naïve Myelofibrosis patients: update of
MANIFEST Phase 2 study
17:45-18:00 Panel discussion
18:05-19:05 SATELLITE SYMPOSIUM
How do you manage treatment failure in myelofibrosis?
Chair: Ruben Mesa (San Antonio, TX, USA)
Speakers: Prithviraj Bose (Houston, TX, USA), Francesco Passamonti (Varese, Italy)
This symposium is organized and sponsored by Bristol Myers Squibb
Sunday, February 28th, 2021
SESSION VI – Treatment free remission in CML
Chair: Susanne Saussele (Mannheim)
09:25-09:30 Introduction Susanne Saussele (Mannheim)
5
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES